We report two cases of salivary gland tumors arising in two psoriatic patients treated with an anti-TNF-alpha agent. A clear causal relationship could not be established, but the exceptional onset of a bilateral Warthin's tumor in one of these patients should be emphasized.
UngariCPaparoFColangeliWIannettiG. Parotid glands tumours: Overview of a 10-year experience with 282 patients, focusing on 231 benign epithelial neoplasms. Rev Med Pharmacol Sci2008; 12(5): 321–5.
2.
TaylorTRCozensNJRobinsonI. Warthin's tumour: A retrospective case. Br J Radiol2009; 82(983):916–9.
3.
AsklingJvan VollenhovenRFGranathF. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: Does the risk change with the time since start of treatment?Arthritis Rheum2009; 60(11): 3180–9.
4.
QuartuccioLDe ReVFabrisM. Atypical lymphoproliferation progressing into B-cell lymphoma in rheumatoid arthritis treated with different biological agents: Clinical course and molecular characterization. Haematologica2006; 91(5):691–4.
5.
SistoMD'AmoreMCaprioSMitoloVScagliusiPLisiS. Tumor necrosis factor inhibitors block apoptosis of human epithelial cells of the salivary glands. Ann NY Acad Sci2009; 1171:407–14.
6.
SistoMLisiSLofrumentoDDCaprioSMitoloVD'AmoreM. TNF blocker drugs modulate human TNF-α-converting enzyme pro-domain shedding induced by autoantibodies. Imunobiology2010; 215(ll):874–83.
7.
SistoMLisiSLofrumentoDDCucciLMitoloVD'AmoreM. Blockade of TNF-α signaling suppresses the AREG-mediated IL-6 and IL-8 cytokines secretion induced by anti-Ro/SSA autoantibodies. Lab Invest2010; Epub ahead of print.
8.
SistoMLisiSLofrumentoDDIngravalloGMitoloVD'AmoreM. Expression of proinflammatory TACE-TNF-α-amphiregulin axis in Sjogren's syndrome salivary glands. Histochem Cell Biol2010; 134(4):345–53.
9.
LisiSSistoMLofrumentoDDCucciLFrassanitoMAMitoloVD'AmoreM. Pro-inflammatory role of Anti-Ro/SSA autoantibodies through the activation of Furin-TACE-amphiregulin axis. J Autoimmun2010; 35(2): 160–70.
10.
LisiSSistoM. Effects of biological drug adalimumab on tumour necrosis factor-alpha-converting enzyme activation. Immunol Cell Biol2010; 88(3):297–304.
